Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + apatinib + nab-paclitaxel + epirubicin + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
This combination regimen is a neoadjuvant therapy being investigated for the treatment of stage II-III triple-negative breast cancer (TNBC). It is the subject of a Phase II clinical trial (NCT05447702) sponsored by West China Hospital. The regimen combines the anti-PD-1 monoclonal antibody camrelizumab with the small molecule VEGFR-2 tyrosine kinase inhibitor apatinib and a standard chemotherapy backbone consisting of nab-paclitaxel followed by epirubicin and cyclophosphamide. The rationale for this combination is to synergize the immune-potentiating effects of PD-1 blockade with the anti-angiogenic and tumor microenvironment-modulating effects of VEGFR inhibition, alongside the direct cytotoxic effects of chemotherapy, to improve pathological complete response rates in patients with aggressive TNBC.
- Other names
- Camrelizumab Plus Apatinib and ChemotherapyApatinib-West China Hospital-TNBC regimen
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on camrelizumab + apatinib + nab-paclitaxel + epirubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + apatinib + nab-paclitaxel + epirubicin + cyclophosphamide.